Hypophosphatasia
Hypophosphatasia (HPP) is a rare genetic disorder characterized by defective mineralization of bones and teeth, leading to symptoms such as weak bones, frequent fractures, and dental issues.
Hypophosphatasia in Children: ALXN1850 Study
We are studying a new treatment, ALXN1850, for children with hypophosphatasia who haven't been treated before. The goal is to see if it improves bone health and quality of life compared to a placebo.
3-6 months16-20 visitsConfirmation phase (III)Post-Trial Drug AccessCost ReimbursementPartially RemoteInvestigational MedicinesInjectionOrthopedics and TraumatologyPediatrics
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 2 and 12 years old?
- Do you have a diagnosis of hypophosphatasia (HPP)?
- Are you currently pregnant or breastfeeding?
- Have you taken any medications like bisphosphonates (e.g., Fosamax, Boniva) in the last 6 months?
- Are you taking any medications that affect bone health, like parathyroid hormone (e.g., Forteo) within the last 2 weeks?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Alxn1850
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
University Childrens Hospital Queen Fabiola
Nutrition and Metabolism Clinic
Jette, Belgium
HUS-Yhtymae
Department of pediatric endocrinology
Helsinki, Finland
Assistance Publique Hopitaux De Paris
Pediatric Endocrinology and Diabetes for Children
Croulebarbe, France
Sponsor: Alexion Pharmaceuticals Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.